Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint
Study: Rencarex Treatment Efficacy Increases With CAIX Antigen Density in Tumor Tissue
DSMB Recommends Discontinuing Phase III Perifosine Combination Trial
51% Control Rate Achieved In Phase II Trial of Elderly Patients
Study: Partial Kidney Removal Leads to Greater Survival
Phase IIb Trial of CRLX101 Fails Overall Survival Endpoint
AIDS Cachexia Drug Stabilizes Body Weight, Muscle Mass
Two Children Achieve Remission With CD19 Immunotherapy
Adjuvant Chemotherapy Unneeded In Children with Low-Risk Disease
Study: Oncotype DX Score Can Predict Local Recurrence
BRAF Mutation Testing Classifies Indeterminate FNA Samples
NCI CTEP Approved Trials For the Month of March
FDA Approves Lymphoseek For Imaging Lymph Nodes
Trending Stories
- “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital
In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process - DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions
- How City of Hope is turning microbiome science into better cancer care
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - FDA clears fruit-flavored vapes, relaxes enforcement on black-market products with pending premarket applications
Critics say policies clear the way for major tobacco companies to enter fruit-flavored vape market - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
